Sentara Brings 1st Minimally Invasive Treatment for Aortic Regurgitation to Virginia - Summary - MDSpire
Advertisement
Sentara Brings 1st Minimally Invasive Treatment for Aortic Regurgitation to Virginia
For decades, open-heart surgery was the only treatment option for people with severe aortic valve disease. Patients too sick to withstand major surgery often faced a steady decline in heart function.
To introduce the JenaValve Trilogy Transcatheter Heart Valve System as a minimally invasive treatment option for patients with aortic regurgitation.
Approach:
Clinical Trial Participation: Sentara Heart Hospital participated in the national ALIGN-AR clinical trial evaluating the JenaValve Trilogy, the first FDA-approved transcatheter valve for aortic regurgitation.
Procedure Implementation: The first two commercial cases using the Trilogy valve were successfully performed at Sentara Heart Hospital on May 4.
Key Findings:
The JenaValve Trilogy is specifically designed for patients with non-calcified valves, addressing a significant treatment gap.
Sentara was one of only 30 sites nationwide to participate in the ALIGN-AR trial, completing 30 procedures and screening over 100 patients.
Interpretation:
The introduction of the Trilogy valve provides a new treatment option for symptomatic aortic regurgitation.
Limitations:
The study's findings are based on a clinical trial setting and may not fully represent outcomes in broader clinical practice.
Conclusion:
Sentara's involvement in the ALIGN-AR trial positions it as a leader in structural heart therapies, offering innovative treatment options to patients.
